Current Oncology, Volume 15, Issue 3

This issue of Current Oncology cuts a broad swath through highly topical subjects in cancer biology and cancer care[...]

Cancer is a systemic disease that can affect nearly every organ in the body, resulting in a progressive loss of organ function. That loss of function may be initially slow, having minimal effect, or it may be rapid, resulting in more dramatic changes...

Fewer than 20% of women with endometrial cancer have positive nodes, and an accurate noninvasive imaging modality to assess lymph node status would be helpful in selecting those who need lymphadenectomy. The objective of this pilot study was to evalu...

Question: What is the role of hormonal therapy as adjuvant therapy in patients with stage I endometrial cancer? Perspectives: There is little consensus on the role of adjuvant treatment for patients with stage I endometrial cancer. Although the use o...

Objective: Monoclonal antibodies (MAbs) such as trastuzumab and bevacizumab have become important yet expensive components of systemic cancer therapy across a variety of disease sites. We assessed the potential cost implications of adopting trastuzum...

The McGill University Department of Oncology has changed and expanded since its inception in 1990, responding to the move to interdisciplinary clinical care, teaching, and research. Although the traditional Divisions have been maintained to correspon...

Background: Despite high-level evidence in the literature, the use of single-fraction radiotherapy (RT) for management of painful bone metastases is not widely practiced in the world, as highlighted in several practice-pattern surveys. Fractionation...

Sunitinib (Sutent: Pfizer, New York, NY, U.S.A.) is an oral multi-targeted tyrosine kinase inhibitor approved for use in various solid tumour malignancies. Many side effects secondary to sunitinib have been documented. In particular, sunitinib admini...

The 3rd Annual Ontario Thoracic Cancer Conference was held March 28–30, 2008, in Niagara-on-the-Lake, bringing together those in community and academic practice throughout the province who have an interest in thoracic oncology. [...]

A review of the randomized clinical trials of adjuvant trastuzumab in human epidermal growth factor receptor (HER2)—positive breast cancer demonstrates the great benefit of this monoclonal antibody whose potential cardiotoxicity is a fascinating prob...